Retagliptin and its Impurities

Retagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor developed for the treatment of type 2 diabetes by increasing incretin levels to improve insulin secretion and blood glucose control. Reference standards of Retagliptin API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.